NCT02619864View on ClinicalTrials.gov

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

March 22, 2019

Study Completion Date

February 25, 2020

Conditions
Glioblastoma Multiforme
Interventions
DRUG

AZD2014

Trial Locations (4)

T2N 4N2

Tom Baker Cancer Centre, Calgary

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

QEII Health Sciences Centre, Halifax

M5G 2M9

University Health Network, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK

NCT02619864 - mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter